SCHEMBL1255540

SCHEMBL1255540

O=C(c1ccccn1)c1sc(NC(=O)C2CCC2)nc1-c1ccco1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
L3MBTL1 Q9Y468 3/20 0.66
KDM4E B2RXH2 2/20 0.66
POLB P06746 2/20 0.66
MEN1 O00255 1/20 0.66
LMNA P02545 1/20 0.66
MAPT P10636 1/20 0.66
PKM P14618 1/20 0.66
KMT2A Q03164 1/20 0.66
ADORA2A P29274 15/20 0.59
ADORA1 P30542 15/20 0.59
ADORA3 P0DMS8 11/20 0.59
ADORA2B P29275 9/20 0.59
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
USP2 O75604 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1256216 0.96 ADORA2A (0.61) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1256298 0.92 ADORA2A (0.57) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1256256 0.91 ADORA2A (0.56) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1254176 0.87 ADORA2A (0.55) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1255524 0.85 ADORA2A (0.69) L3MBTL1ADORA2AADORA1ADORA3ADORA2B
SCHEMBL1256864 0.85 ADORA2A (0.55) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1256056 0.84 ADORA2A (0.51) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1254443 0.84 ADORA2A (0.49) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1255697 0.84 ADORA2A (0.64) ALDH1A1L3MBTL1KDM4EPOLBMEN1
SCHEMBL1254709 0.82 ADORA2A (0.62) ALDH1A1L3MBTL1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 ALDH1A1 1344/4885L3MBTL1 436/4885KDM4E 4495/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA ALDH1A1 769/4885L3MBTL1 702/4885KDM4E 4497/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 ALDH1A1 1290/4885L3MBTL1 2618/4885KDM4E 4728/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 ALDH1A1 2843/4885L3MBTL1 2473/4885KDM4E 4715/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 ALDH1A1 638/4885L3MBTL1 1732/4885KDM4E 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.